Systemic Amyloidosis
📧 Sign up to get email alerts when something new happens for Systemic Amyloidosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-09Clinical Trial Update: Optimize First-line Treatment for AL Amyloidosis With t (11; 14) [NA]
A clinical trial is ongoing to optimize first-line treatment for systemic AL amyloidosis with the t(11;14) translocation; the study is curre…
-
CLINICAL_TRIALS trial_result · 2025-09-04Clinical Trial Update: A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis [Phase 2]
Phase 2 study update assessing the repeatability of organ-level uptake of the radiopharmaceutical AT-01 labeled with iodine-124 in subjects …
-
CLINICAL_TRIALS trial_result · 2025-08-24Clinical Trial Update: A Study of AT-02 in Subjects With Systemic Amyloidosis. [Phase 2]
AT-02 is being studied in a Phase 2 trial for systemic amyloidosis and is currently recruiting.
-
CLINICAL_TRIALS research · 2025-08-21Clinical Trial Update: Essen Amyloidosis Registry
Clinical trial registry update for the Essen Amyloidosis Registry, a recruiting study at University Hospital Essen evaluating systemic and c…
-
CLINICAL_TRIALS trial_result · 2025-05-01Clinical Trial Update: Body Composition in Systemic Amyloidosis
A completed clinical study update examining body composition in individuals with systemic amyloidosis.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-03-10Clinical Trial Update: Observational Epidemiological Study of Patients Suffering From Systemic Amyloidosis
An observational epidemiological study of patients with systemic amyloidosis, including cardiomyopathy, is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-02-27Clinical Trial Update: S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis [Phase 2]
This update reports results from a Phase 2 trial of isatuximab (S1702) in relapsed or refractory primary systemic amyloidosis. Results were …
-
CLINICAL_TRIALS research · 2024-12-30Clinical Trial Update: Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis [Phase 2]
Phase 2 clinical trial evaluating bortezomib, pomalidomide, and dexamethasone for systemic amyloidosis; currently recruiting.
-
CLINICAL_TRIALS trial_result · 2024-12-05Clinical Trial Update: Repeat PET/CT Imaging of Patients With Amyloid 124I-AT-01 to Measure Changes in Organ-specific Amyloid Load [Phase 2]
Phase 2 trial update assessing changes in organ-specific amyloid load using repeat PET/CT imaging with the tracer Amyloid 124I-AT-01 in pati…
-
CLINICAL_TRIALS trial_result · 2023-06-22Clinical Trial Update: High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis [Phase 2]
Phase 2 trial update evaluating high-dose melphalan with peripheral stem cell transplantation in patients with primary systemic amyloidosis.
-
CLINICAL_TRIALS trial_result · 2023-05-30Clinical Trial Update: Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis [Phase 2]
Phase II trial update for Enbrel in patients with primary systemic amyloidosis has completed.
-
CLINICAL_TRIALS trial_result · 2023-05-24Clinical Trial Update: Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients [Phase 2]
A Phase 2 clinical trial evaluating propylene glycol-free melphalan hydrochloride (Evomela) in systemic amyloidosis (AL type) has been termi…
-
CLINICAL_TRIALS trial_result · 2022-05-10Clinical Trial Update: Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis [Phase 2]
Phase 2 trial evaluating daratumumab with bortezomib and dexamethasone for systemic light chain amyloidosis (AL) in Mayo 04 Stage III.
-
CLINICAL_TRIALS trial_result · 2022-03-25Clinical Trial Update: 124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis [Phase 1, Phase 2]
Clinical trial update on 124I-p5+14 injection safety in systemic amyloidosis reported as completed.
-
CLINICAL_TRIALS trial_result · 2020-09-17Clinical Trial Update: Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis [Phase 2]
Phase 2 trial update evaluating tandem autologous stem cell transplantation in patients with primary systemic (AL) amyloidosis.
-
CLINICAL_TRIALS trial_result · 2020-01-07Clinical Trial Update: Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial [Phase 2]
Phase 2 trial update investigating doxycycline to upgrade organ response in light chain (AL) amyloidosis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-05-29Clinical Trial Update: The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis [Phase 3]
Phase 3 trial of NEOD001 for AL amyloidosis was terminated; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2018-07-24Clinical Trial Update: A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis [Phase 1]
This is a completed Phase 1 study evaluating the safety of GSK2398852 when co-administered with GSK2315698 in patients with systemic amyloid…
-
CLINICAL_TRIALS trial_result · 2017-04-25Clinical Trial Update: Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed [Phase 2]
The document reports a Phase 2 clinical trial of Lendexal in newly diagnosed primary systemic amyloidosis (AL). The study status is listed a…
-
CLINICAL_TRIALS trial_result · 2017-04-07Clinical Trial Update: Study of Bortezomib +HSCT in Primary Systemic Amyloidosis (AL) [NA]
This document notes the completion of a clinical trial evaluating the combination of bortezomib with hematopoietic stem cell transplantation…
-
CLINICAL_TRIALS trial_result · 2017-02-06Clinical Trial Update: Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis [Phase 2]
Phase 2 clinical trial evaluating melphalan, bortezomib, and autologous stem cell transplant for primary systemic amyloidosis; results were …
-
CLINICAL_TRIALS trial_result · 2016-08-10Clinical Trial Update: Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis [Phase 2]
A Phase 2 trial evaluated a sequence of melphalan with autologous stem cell transplant followed by bortezomib and dexamethasone in patients …
-
CLINICAL_TRIALS trial_result · 2015-07-21Clinical Trial Update: Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis [Phase 3]
A Phase 3 trial compares low-dose melphalan with dexamethasone to high-dose melphalan with autologous stem cell transplant in primary system…
-
CLINICAL_TRIALS trial_result · 2015-03-30Clinical Trial Update: Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease [Phase 2]
Phase 2 trial evaluating bortezomib, melphalan, and dexamethasone in treating primary systemic amyloidosis and light chain deposition diseas…
-
CLINICAL_TRIALS trial_result · 2014-11-26Clinical Trial Update: Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis [Phase 3]
Phase 3 trial evaluating melphalan and dexamethasone with or without bortezomib in previously untreated systemic light-chain amyloidosis (pr…